clinical trial · NCT06619860
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated·phase2·recruiting·n = 300
Diabetic Peripheral Neuropathic PainVX-993PregabalinPlacebo (matched to pregabalin)Placebo (matched to VX-993)
brief summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of VX-993 in participants with pain associated with Diabetic Peripheral Neuropathy (DPN)
started
Oct 18, 2024
primary completion
Apr 30, 2026
completion
May 30, 2026
last updated
Apr 21, 2026
official title
A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of Oral VX-993 in Subjects With Pain Associated With Diabetic Peripheral Neuropathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol